Endocrine Abstracts

Introduction: Platinum-etoposide chemotherapy is a globally established chemotherapy combination for EP-G3-NEC. However, there are many different schedules for such chemotherapy, and the preferred one for EP-G3-NEC has not been established.Methods: An international survey was created, and completed by colleagues with an expertise in the field of neuroendocrine neoplasms. The aim was to explore which schedules of platinum-etoposide chemotherapy are used a...

Background: Liver embolisation is one of the treatment options available for patients diagnosed with neuro-endocrine neoplasms (NEN), especially in the presence of carcinoid syndrome. It is still uncertain whether the benefits of the various types of embolisation treatments truly outweigh the complications in NENs. This systematic review assesses the available data relating to liver embolisation in patients with NENs.Methods: Eligible studies (identified...

Background: Neuroendocrine tumours (NETs) are rare malignancies; over 60% of primary lesions arise in the gastrointestinal tract and pancreas. Despite several practice-changing clinical trials, uncertainty persists around the most efficacious treatment sequence in patients with advanced well-differentiated gastroenteropancreatic (GEP) NETs, particularly in relation to peptide receptor radionuclide therapy (PRRT). This study aimed to investigate the progression-free survival (P...

Simultaneous knockout of the neuroendocrine marker genes Ptprn and Ptprn2, which encode the protein tyrosine phosphatase receptors N and N2, respectively, causes infertility of female mice while males are fertile. To clarify the mechanism of sex-specific roles of Ptprn and Ptprn2 in mice reproduction, we analyzed the effects of their double knockout (DKO) on the hypothalamic-pituitary-gonadal axis. In DKO females, a delay in puberty and lack...

Background: Hepatic arterial embolisation (HAE) is a recommended treatment option for patients with neuro-endocrine neoplasms (NENs) and liver metastasis. We aimed to describe outcomes after HAE for NENs at a single United Kingdom centre and investigate the influence of tumour characteristics.Methods: Retrospective analysis of sequential patients with NENs undergoing HAE at The Christie NHS Foundation Trust between 2004 and 2018. Primary end points were ...

Background: New nuclear medicine imaging techniques have improved diagnosis, staging and treatment planning for BC. 68Ga-DOTA PET is preferable to standard somatostatin receptor scintigraphy where available (ENETS guidelines); however, its role in the management of BC remains unclear.Methods: All consecutive patients diagnosed with BC from two ENETS Centres of Excellence were identified retrospectively; patients with high grade tumours or lack...

Background: Despite encouraging advances in the systemic therapy options for patients with pNETs (sunitinib and everolimus), no predictive biomarkers have been established for these drugs. We aimed to identify distinctive genomic alterations associated with benefit from treatment in patients with pNETs, by comparing exceptional-responders (ER) to poor-responders (PO).Methods: Patients who achieved an objective radiological response (complete or partial) ...

Background: Neuroendocrine tumours (NETs) are often associated with SPMs. This study aimed to identify SPMs in patients with non-pulmonary wdNETs.Methods: Patients seen at The Christie with non-pulmonary wdNETs from 2003–2017 were included. After exclusion of patients with hereditary predispositions, notes were retrospectively reviewed for location, functionality, treatment and temporal relation to diagnosis.Results: Of 854 pa...

Background: The prevalence of neuroendocrine neoplasms (NENs) among younger adults is low; clinical management mirrors that in older cohorts. This study aimed to review presentation, disease trajectory and survival outcomes according to treatment in patients aged 18-40 years (y).Methods: An electronic database was searched (retrospectively) for patients with NENs (18-40y) (cut-off May 2023). Patients with VHL, tuberous s...

Introduction: Platinum-etoposide is considered standard-of-care first-line treatment for patients diagnosed with advanced EP-PD-NECs. The optimal platinum-etoposide schedule remains undefined; carboplatin is often substituted for cisplatin, although quality data is lacking.Methods: Electronic records of patients with advanced EP-PD-NEC treated with carboplatin-etoposide (06/09-02/17) were reviewed retrospectively, with aim to provide real-life efficacy/s...